Pari Pharma said this week that its Lamira nebulizer won approval from the FDA to deliver Insmed’s Arikayce amikacin liposome inhalation suspension for the treatment of MAC lung disease.
The company’s Lamira drug-device combination product is intended to be used as part of a combination antibacterial drug regimen for adult patients with limited or no alternative options for treatment, according to Pari Pharma.
Get the full story at our sister site, Drug Delivery Business News.
The post Pari Pharma lands FDA nod for Lamira nebulizer appeared first on MassDevice.